Loading patent…
AssigneesLaboratorios Del Dr. Esteve, S.A., Fundacio Privada Institut De Recerca De La Sida—Caixa, Institució Catalana De Recerca I Estudis AvançAts, Ruprecht-Karls-Universitaet Heidelberg
InventorsNuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
Estimating the term…
The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
A method for blocking the entry of HIV into dendritic cells in a subject in need thereof, said method comprising administering to said subject an inhibitor of the interaction between sialoadhesin and sialyllactose, wherein said inhibitor is a vesicle comprising a molecule comprising a sialyllactose moiety, and wherein said molecule is a ganglioside having less than four sialic acids.
Dependencies are inferred from the claim text.